• Adult patients who meet all the following criteria at screening may be included in the study:
• Are between ≥ 18 years and ≤ 85 years at the signing of informed consent
• Have a history of chronic HFrEF, defined as requiring treatment for HF for a minimum of 3 months prior to screening
• Are receiving oral loop diuretics
• Patients without AFF on screening ECG:
LVEF < 30% within 6 months of screening
Elevated N-terminal prohormone of B-type natriuretic peptide (NT-proBNP) ≥ 1000 pg/mL (BNP ≥ 300 pg/mL)
• Patients with AFF on screening ECG:
LVEF < 25% within 6 months of screening
Elevated N-terminal prohormone of B-type natriuretic peptide (NT-proBNP) ≥ 3000 pg/mL (BNP ≥ 900 pg/mL)
Not currently taking digoxin
• Are currently hospitalized with the primary reason of HF, or had an HF event within 6 months prior to screening
• Are established on regional standard-of-care HF therapies for at least 30 days prior to screening
• Systolic blood pressure ≤ 130 mmHg and diastolic blood pressure ≤ 90 mmHg

Any of the following criteria will exclude potential patients from the study:
• Have AFF on the screening ECG and are currently taking digoxin
• Have had acute coronary syndrome, cardiac surgery, valve surgery, any coronary revascularization, and/or cardiac resynchronization therapy within 3 months of screening
• Are admitted to a long-term care facility or hospice
• Have a projected survival of < 12 months due to non-cardiovascular causes based on clinical judgment
• Are receiving intravenous inotropes or intravenous vasopressors ≤ 3 days prior to screening
• Are receiving mechanical hemodynamic support or mechanical ventilation ≤ 7 days prior to screening
• Are receiving intravenous diuretics, intravenous vasodilators, or supplemental oxygen therapy ≤ 12 hours prior to screening
• Have an estimated glomerular filtration rate (eGFR) < 20 mL/min/1.73m2 or receiving dialysis at screening
• Have previously had a solid organ transplant
• Are receiving treatment in another investigational device or drug study or are within 30 days of ending such investigational treatment at screening
• Have previously received omecamtiv mecarbil
• Are pregnant or planning pregnancy during the study period, or planning to breastfeed during treatment with IP or within 5 days after the end of treatment with IP

• Cardiology

• omecamtiv mecarbil

• CK-1827452

• Cytokinetics